LEO roars into acne space with KLOX medtech deal

LEO Pharma, the privately held Danish skin disease specialist, is fulfilling a five-year strategic ambition by linking up with Canadian medtech firm KLOX Technologies. LEO and KLOX have entered into a worldwide license and joint venture agreement, excluding Canada, to further develop and commercialize the Canadian firm's BioPhotonic technology platform, which includes a CE-approved treatment for moderate to severe acne.

LEO Pharma, the privately held Danish skin disease specialist, is fulfilling a five-year strategic ambition by linking up with Canadian medtech firm KLOX Technologies. LEO and KLOX have entered into a worldwide license and joint venture agreement, excluding Canada, to further develop and commercialize the Canadian firm's BioPhotonic technology platform, which includes a CE-approved treatment for moderate to severe acne.

While commercial terms have not been disclosed, LEO CEO and president Gitte Aabo confirmed to Scrip that her company's investment...

More from Dermatological

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By 

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By 

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

More from Therapy Areas

PureTech Ponders Way Forward As CEO Exits

 
• By 

Bharatt Chowrira departs days after firm’s chair stepped down.

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?

Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist

 
• By 

With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.